Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Take over process..in general

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Mar 14, 2024 4:11pm

189 Views

Post# 35933494

RE:RE:Take over process..in general

Not arguing. Just thinking about buying more now or later. If it is going to quiet for awhile which appears to be the case then I wait. What ONC really needs at whatever stage their in, is promotion and not by an ad at a hockey game, or by company sponsored pr firm, or by in house scientists but by some highly recognized independent source even just to get the ball rolling

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta